Logmein (LOGM) Stake Upped by Systematic Financial Management Lp; Myriad Genetics (Put) (MYGN) Shareholder Sg Capital Management Has Lowered Stake by $6.59 Million as Valuation Declined

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo

Systematic Financial Management Lp increased its stake in Logmein Inc. (LOGM) by 27.12% based on its latest 2019Q2 regulatory filing with the SEC. Systematic Financial Management Lp bought 27,337 shares as the company’s stock declined 6.24% . The institutional investor held 128,129 shares of the technology company at the end of 2019Q2, valued at $9.44M, up from 100,792 at the end of the previous reported quarter. Systematic Financial Management Lp who had been investing in Logmein Inc. for a number of months, seems to be bullish on the $3.71 billion market cap company. The stock decreased 4.76% or $3.8 during the last trading session, reaching $76. About 320,774 shares traded. LogMeIn, Inc. (NASDAQ:LOGM) has declined 6.50% since December 4, 2018 and is downtrending. It has underperformed by 6.50% the S&P500. Some Historical LOGM News: 21/05/2018 – LogMeln CFO Edward Herdiech Named Boston Business Journal 2018 CFO of the Year Honoree; 20/04/2018 – DJ LogMeIn Inc, Inst Holders, 1Q 2018 (LOGM); 26/04/2018 – LOGMEIN 1Q ADJ EPS $1.21, EST. $1.18; 10/05/2018 – LogMeIn’s Jive and GoToStage Win Stevie® Awards for New Product or Service of the Year from the 2018 American Business Award; 13/03/2018 LastPass Recognized in Independent Research Firm Enterprise Password Management Vendor Landscape Report; 09/04/2018 – LogMeln Names Sara Andrews to Board of Directors; 26/04/2018 – LogMeIn Sees FY18 EPS 85c-EPS 96c; 23/03/2018 – LOGMEIN ENTERED BORROWER ACCESSION AGREEMENT; 04/05/2018 – Mackenzie Canadian Large Dividend Adds LogMeIn; 20/04/2018 – LogMeIn Closes Below 50-Day Moving Average: Technicals

Sg Capital Management Llc decreased its stake in Myriad Genetics Inc (Put) (MYGN) by 69.77% based on its latest 2019Q2 regulatory filing with the SEC. Sg Capital Management Llc sold 244,200 shares as the company’s stock declined 8.71% . The hedge fund held 105,800 shares of the health care company at the end of 2019Q2, valued at $2.94 million, down from 350,000 at the end of the previous reported quarter. Sg Capital Management Llc who had been investing in Myriad Genetics Inc (Put) for a number of months, seems to be less bullish one the $1.90B market cap company. The stock increased 3.31% or $0.82 during the last trading session, reaching $25.6. About 148,009 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 31.84% since December 4, 2018 and is downtrending. It has underperformed by 31.84% the S&P500. Some Historical MYGN News: 17/05/2018 – Myriad Genetics Presenting at Conference Jun 4; 12/03/2018 – Myriad Genetics ‘Cooperating With Government’s Request’; 08/05/2018 – The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018; 07/05/2018 – Myriad Genetics: Data Show 50% Improvement in Remission and 30 % Improvement in Response for GeneSight Versus Treatment as Usual; 26/04/2018 – The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Myriad; 31/05/2018 – GeneSight® Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting; 12/03/2018 – MYRIAD GENETICS – SUBPOENA REQUESTED CO PRODUCE DOCUMENTS RELATED TO BILLING TO GOVT-FUNDED HEALTHCARE PROGRAMS FOR HEREDITARY CANCER TESTING; 26/05/2018 – DEADLINE ALERT: Shareholder Class Action Against Myriad Genetics, Inc. — MYGN; 16/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN); 19/03/2018 – Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. (MYGN) on Behalf of Stockholders and Encourages Investors to Contact the Firm

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Globenewswire.com which released: “GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions – GlobeNewswire” on November 06, 2019, also Benzinga.com with their article: “10 Healthcare Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” published on November 05, 2019, Globenewswire.com published: “Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm – GlobeNewswire” on November 13, 2019. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Finance.Yahoo.com and their article: “Independent Chairman John Henderson Just Bought Shares In Myriad Genetics, Inc. (NASDAQ:MYGN) – Yahoo Finance” published on November 10, 2019 as well as Benzinga.com‘s news article titled: “Mid-Day Market Update: EverQuote Rises After Upbeat Q3 Results; Armstrong Flooring Shares Plummet – Benzinga” with publication date: November 05, 2019.

Sg Capital Management Llc, which manages about $427.20 million and $631.76M US Long portfolio, upped its stake in Mastec Inc (NYSE:MTZ) by 179,089 shares to 379,089 shares, valued at $19.53 million in 2019Q2, according to the filing. It also increased its holding in Varex Imaging Corp (Put) by 245,600 shares in the quarter, for a total of 251,600 shares, and has risen its stake in Universal Fst Prods Inc (NASDAQ:UFPI).

Investors sentiment increased to 1.08 in Q2 2019. Its up 0.03, from 1.05 in 2019Q1. It improved, as 29 investors sold MYGN shares while 61 reduced holdings. 22 funds opened positions while 75 raised stakes. 77.57 million shares or 1.24% more from 76.62 million shares in 2019Q1 were reported. National Bank & Trust Of America Corporation De owns 172,516 shares or 0% of their US portfolio. Employees Retirement System Of Texas reported 0.01% stake. Sg Cap Limited Liability Corp has 2.21% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 501,818 shares. Tower Rech Capital Ltd Liability Com (Trc) reported 148 shares. Guggenheim Limited Liability Company owns 0.03% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 118,440 shares. Hall Laurie J Trustee has 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Deutsche Comml Bank Ag stated it has 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Mcf Limited invested in 0% or 1,011 shares. Prudential Financial has invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Cornerstone Advsrs holds 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN) for 140 shares. Stifel Corporation owns 76,427 shares for 0.01% of their portfolio. Birchview Cap Limited Partnership has 0.34% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Aperio Grp Inc invested in 21,815 shares or 0% of the stock. Disciplined Growth Investors Mn holds 2.71 million shares. Continental Advsr Limited Company reported 13,892 shares.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on February, 4. They expect $0.23 earnings per share, down 23.33% or $0.07 from last year’s $0.3 per share. MYGN’s profit will be $17.11 million for 27.83 P/E if the $0.23 EPS becomes a reality. After $-0.03 actual earnings per share reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -866.67% EPS growth.

Investors sentiment decreased to 0.75 in Q2 2019. Its down 0.49, from 1.24 in 2019Q1. It turned negative, as 40 investors sold LOGM shares while 110 reduced holdings. 43 funds opened positions while 69 raised stakes. 45.73 million shares or 2.94% more from 44.42 million shares in 2019Q1 were reported. Trexquant Inv Ltd Partnership accumulated 5,696 shares or 0.04% of the stock. Pinebridge Investments Ltd Partnership reported 85,633 shares. Us Commercial Bank De has 2,244 shares. Alps Advisors invested in 9,561 shares or 0.01% of the stock. Price T Rowe Assoc Md, Maryland-based fund reported 285,392 shares. Charles Schwab Invest has 0.01% invested in LogMeIn, Inc. (NASDAQ:LOGM) for 324,601 shares. Baldwin Brothers Ma owns 0% invested in LogMeIn, Inc. (NASDAQ:LOGM) for 343 shares. The New York-based Alliancebernstein Ltd Partnership has invested 0% in LogMeIn, Inc. (NASDAQ:LOGM). Massachusetts-based Sirios Capital Management Limited Partnership has invested 0.89% in LogMeIn, Inc. (NASDAQ:LOGM). 26,909 were reported by State Of Tennessee Treasury Department. Quantbot Techs LP reported 0.01% stake. Aqr Cap Lc holds 0.04% or 506,015 shares. Nj State Employees Deferred Compensation Plan stated it has 3,436 shares or 0.05% of all its holdings. Commonwealth Of Pennsylvania School Empls Retrmt System holds 0.01% or 8,780 shares in its portfolio. Ftb Advsrs Inc accumulated 2 shares.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.